Adaptimmune Therapeutics plc (473A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has a cash flow conversion efficiency ratio of 0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-34.78 Million ≈ $-40.66 Million USD) by net assets (€-70.96 Million ≈ $-82.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Adaptimmune Therapeutics plc stock valuation for the company's overall valuation and market capitalisation.
Adaptimmune Therapeutics plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Adaptimmune Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adaptimmune Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptimmune Therapeutics plc ranked by their cash flow conversion efficiency. Explore Adaptimmune Therapeutics plc (473A) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
GenMont Biotech Inc
TW:3164
|
0.011x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
OS Therapies Incorporated
NYSE MKT:OSTX
|
-1.000x |
|
Next Bt Co. Ltd
KQ:065170
|
-0.031x |
|
Huvis Corporation
KO:079980
|
-0.024x |
|
AXIOS Sustainable Growth
NYSE:AXAC
|
-0.003x |
|
Sand Nisko Capital Bhd
KLSE:7943
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Adaptimmune Therapeutics plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Adaptimmune Therapeutics plc from 2016 to 2024. View 473A live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €11.85 Million ≈ $13.85 Million |
€-73.21 Million ≈ $-85.59 Million |
-6.178x | -73.28% |
| 2023-12-31 | €39.51 Million ≈ $46.19 Million |
€-140.88 Million ≈ $-164.70 Million |
-3.565x | -105.92% |
| 2022-12-31 | €81.88 Million ≈ $95.72 Million |
€-141.77 Million ≈ $-165.74 Million |
-1.731x | -3423.82% |
| 2021-12-31 | €205.96 Million ≈ $240.79 Million |
€10.73 Million ≈ $12.54 Million |
0.052x | +133.17% |
| 2020-12-31 | €341.23 Million ≈ $398.93 Million |
€-53.59 Million ≈ $-62.65 Million |
-0.157x | +82.74% |
| 2019-12-31 | €123.64 Million ≈ $144.55 Million |
€-112.51 Million ≈ $-131.53 Million |
-0.910x | -115.21% |
| 2018-12-31 | €246.88 Million ≈ $288.63 Million |
€-104.39 Million ≈ $-122.04 Million |
-0.423x | -58.01% |
| 2017-12-31 | €202.98 Million ≈ $237.31 Million |
€-54.31 Million ≈ $-63.50 Million |
-0.268x | +7.70% |
| 2016-12-31 | €166.14 Million ≈ $194.24 Million |
€-48.17 Million ≈ $-56.31 Million |
-0.290x | -- |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more